Major Growth Drivers:

What are the key factors driving demand for targeted allergy drugs in the global marketplace?

• Growing incident rates of diseases of the respiratory system, atopic dermatitis corticosteroids
• Rapid advancements in drug development in the area of biologics by leading pharmaceutical companies
• Rising awareness of allergic diseases and increased numbers of diagnostics indicates there is a comprehensive need for a larger number of patients to receive targeted therapies
• The shift to personalized medicine. As the market for pharmaceuticals becomes increasingly personalized to the demographics and psychology of individual patients, more healthcare practitioners will be deploying the use of targeted allergy drugs.

  Key Drifts:

  Trends Impacting the Future of Targeted Drugs for Allergic Diseases Market:

  There are many trends that will define the outlook of the targeted drugs for allergic diseases market. Key trends include such as, increased biologic use, movement towards self-administration of medicine, increased availability and affordability of biosimilars increasing digital health infrastructure
  Become a valued research partner with us -

  Significant Challenge:

  One of the largest barriers to the use of targeted allergy drug treatment is the cost. The majority of targeted allergy treatments currently available worldwide are only accessible to wealthier people due to their significant costs and the fact that there are significant barriers to using these therapies in developing countries. Even in developed countries, reimbursement barriers and restrictions on insurance claims may limit access to the overwhelming majority of patients.

  In addition to this, many patients do not have a good understanding of the long-term benefits of biologics

  Regional Analysis:

  North America had the largest targeted drugs for allergic diseases market by 40% at the end of 2024. There are three major factors driving this growth; North America has a very strong and fully developed biotech industry, which has resulted in the development of a very sophisticated health care system, the rapid growth of the use of new types of targeted biologics and an ever-increasing number of FDA approved targeted allergy drugs will allow for quick entry into the market for new molecules such as mono- and cytokine inhibitors.

  • Additionally, the growing number of asthma, eczema, and food allergies will continue to drive the development of new targeted therapies. There is already a well-established system of reimbursement support, which makes it easier for companies to manufacture targeted allergy drugs.
    

  The Asia Pacific will see growth that far exceeds previously forecasted growth rates for the targeted drugs for allergic diseases market because of the rapid rise in asthma and food allergies in the Asia-Pacific population caused by increasing urbanization. Other factors leading to the rapid growth in targeted allergy treatment in Asia Pacific include the increase in disposable income and the increased focus of governments on managing chronic disease. Because of the increasing amount of disposable income and the emphasis that governmental bodies are placing on the prevention and treatment of chronic disease, the targeted allergy drug market is likely to grow extremely fast in all of the Asian countries.

  Get the latest insights on life science industry segmentation with our Annual Membership:

  Segmental Insights:

  By Drug Type:

  In 2024, monoclonal antibodies segment led the targeted drugs for allergic diseases market. These products are being used increasingly as the primary treatment option for people who suffer from moderate-to-severe asthma, atopic dermatitis, and chronic urticaria because of the high efficacy (effectiveness) and precise mechanism of action. By neutralising certain cytokines (chemical messengers) and immunoglobulins (the body's natural antibodies), monoclonal antibodies can provide long-term relief of symptoms with the minimisation of acute flare-ups.

  The anti-IgE/anti-IL biologics segment will be the fastest growing segment of the overall targeted drugs for allergic diseases market during the forecast period due to increasing acceptance of the use of precision therapies that target specific immune pathways. The current trend is towards the use of precision therapies to provide enhanced control to patients with severe or treatment-resistant allergic disorders and is therefore seen as desirable by clinicians. The expanding availability of drugs such as omalizumab ("Xolair"), dupilumab ("Dupixent") and the expected emergence of the new IL-5/IL-13 antagonist class of drugs, will further expand the clinical use of these drugs in patients with allergy-related diseases.

  By indication:

  The dominant market segment for allergy drugs in the market was asthma, this continued growth reflects an increase in asthma rates globally, particularly in urban areas with high levels of air pollution. Biologics that target pathways leading to symptoms of asthma have changed how patients manage their asthma; these drugs have provided the ability to treat the root causes of asthma

  Atopic dermatitis was one of the markets expected to be the fastest growing due to a rise in moderate-to-severe atopic dermatitis and an increase in the awareness of patients and physicians regarding the need for specialized therapies. Traditionally, topical therapies do not adequately control systemic inflammation and as a result physicians are now recommending targeted biologics (IL-4/IL-13) as the future of treatment for these patients. These drugs provide significant improvements in eczema lesions, itching and the management of symptoms over the long term. In addition to an increase in the availability of recommended therapeutics and improved techniques for diagnosing and treating atopic dermatitis, the availability of novel biologic agents will spur further growth in this market.

  By mechanism of action:

  In 2024 the market was dominated by the anti-IgE pathway Inhibitors segment with approximately 24% of total market revenues; the majority of this revenue was generated from sales of the product, omalizumab. Anti-IgE drugs are effective because they neutralize IgE, thus eliminating the cascade of allergic responses that leads to symptoms of asthma, dermatitis, and urticaria. The clinical success of anti-IgE therapies, the long-term safety and effectiveness of therapies like omalizumab, and the versatility of anti-IgE therapies to treat multiple allergic conditions have contributed to the continued strength of this segment.

  IL-4/IL-13 pathway blockers segment is projected to be the fastest growing segment due to the strong clinical results being achieved with targeted biologics for asthma and atopic dermatitis. IL-4/IL-13 Biologics target the central cytokines involved in allergic/IgE mediated inflammation. Patients are demonstrating increased demand for advanced biologic therapies, thus, in turn, increasing the need for companies to advance their portfolio to include next-generation IL-4/IL-13 inhibitors.

  By Route of Administration:

  By 2024, it is predicted that roughly 55% of the total market share would be provided by the subcutaneous injection route. Patient-administered biologic medications for the treatment of allergic diseases most often provide this route due to the ability for easy administration and increased bioavailability. The patient preference for self-administration and receiving medication at home has contributed significantly to the growth of this route. Also, due to advisable dosing-control and decreased patient visits to the hospital, the subcutaneous route is generally preferred by healthcare providers for delivering biologic medications.

  The oral route of delivery has been predicted to be the fastest-growing segment of this market on account of pharmaceutical companies developing next-generation oral immunotherapies and small-molecule inhibitors. Oral formulations are easier for patients to take and are non-invasive compared to injections; therefore, they provide patients with an attractive alternative. Therapies directed toward specific immune pathways that are in the process of emerging for human-use clinical trials will produce tremendous potential for new products.

  By End-User:

  As of 2024, approximately 45% of the total sales of biologics were derived from the use of hospitals and specialty clinics. These facilities support the growing demand for the many sophisticated allergy treatments due to their capacity to provide diagnostic devices, expertise, and clinic-based monitoring for the effectiveness of biologics.

  Due to increasing convenience and the demand for remote treatment alternatives, the homecare/self-administration end-user category will experience the largest growth in the coming years. Technology has allowed the development of auto-injectors, transportable biologics, and remote monitoring procedures; therefore, self-administered biologics are now a possibility. As the amount of information available for patients to determine whether they would be better off receiving allergy treatment via a self-administered route increase, the reliance of patients on clinics for support will decline; thus, increasing overall acceptance.

  Browse More Insights of Towards Healthcare:

  The global infectious diseases market size

  The global drug discovery platforms market size

  The global oncology drugs market size

  The anticancer drugs market size

  The global CRISPR technology market size

  The RNAi therapeutics market

  The global myasthenia gravis treatment market size

  The molecular diagnostics market

  The hepatitis A vaccine market

  The global pulmonary arterial hypertension drugs market

  Recent Developments:

  • In March 2025, Dupixent (dupilumab) approved in Japan for COPD: The drug received regulatory authorization from Japan's Ministry of Health, Labour and Welfare for use in adults with inadequately controlled chronic obstructive pulmonary disease (COPD) having an eosinophilic phenotype, representing the first biologic approval for COPD in Japan in over a decade.
    

  Targeted Drugs For Allergic Diseases Market Key Players List:

  • Sanofi S.A.
  • Regeneron Pharmaceuticals Inc.
  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc
  • Amgen Inc.
  • Eli Lilly and Company
  • AbbVie Inc.
  • Roche/Genentech
  • Johnson & Johnson
  • Kyowa Kirin Co. Ltd.
  • Chugai Pharmaceutical Co. Ltd.
  • ALK-Abelló A/S
  • Amgen–AstraZeneca Alliance
  • Takeda Pharmaceutical Co. Ltd.
  • Biogen Inc.
  • Glenmark Pharmaceuticals
  • Hanmi Pharmaceutical Co. Ltd.
  • Suzhou Connect Biopharma
    

  Segments Covered in the Report

  By Drug Class/Type

  • Monoclonal Antibodies (mAbs)
  • Small-Molecule Inhibitors (e.g., JAK, S1P, PDE4)
  • Anti-IgE and Anti-IL Biologics (Omalizumab, Dupilumab, Mepolizumab, etc.)
  • Allergen-Specific Immunotherapy (SCIT, SLIT)
  • Others (Novel peptides, recombinant proteins)
    

  By Indication

  • Asthma (Moderate-to-Severe, Eosinophilic, Allergic)
  • Atopic Dermatitis (Eczema)
  • Allergic Rhinitis & Conjunctivitis
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
  • Food Allergy & Anaphylaxis
  • Urticaria & Other Allergic Conditions

  By Mechanism of Action

  • Anti-IgE Pathway Inhibitors
  • IL-4/IL-13 Pathway Blockers
  • IL-5/IL-5R Inhibitors
  • JAK/TYK2 Inhibitors
  • Others (IL-31, IL-33, S1P Modulators, CRTH2 Antagonists)
    

  By Route of Administration

  • Subcutaneous Injection (Prefilled Syringes/Autoinjectors)
  • Intravenous Infusion
  • Oral (JAK, PDE4 Inhibitors)
  • Sublingual / Nasal / Inhaled Immunotherapy

  By End User

  • Hospitals & Specialty Clinics
  • Allergy & Immunology Centers
  • Homecare/Self-administration Patients
  • Academic & Research Institutions
  • Contract Research & Manufacturing Organizations (CROs/CMOs)
    

  By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
      
  Immediate Delivery Available | Buy This Premium Research @

  Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

  Access the Dashboard:

  About Us

  Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research
  You can place an order or ask any questions, please feel free to contact us at ...

  Europe Region: +44 778 256 0738

  North America Region: +1 8044 4193 44

  APAC Region: +91 9356 9282 04

  Web:

  Our Trusted Data Partners

  Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
  Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest